![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Human Metabolism Section, Laboratory of Pharmacology and Chemistry (Y.C., S.S.F., J.A.G.) and Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology (M.N.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina
Human CYP2C9 is important in the metabolism of numerous clinically used drugs such as the anticoagulant warfarin, the anticonvulsant phenytoin, antidiabetic drugs such as tolbutamide and glipizide, the hypertensive agent losartan, and numerous nonsteroidal anti-inflammatory drugs. Several studies have reported that certain drugs such as rifampicin and phenobarbital induce CYP2C9, but the molecular basis for this induction remains unknown. In the present study, we demonstrate that the human pregnane X receptor (hPXR) mediates induction of CYP2C9 by the prototype drugs rifampicin, hyperforin (found in St. John's Wart), and phenobarbital. Deletion and mutagenesis studies with luciferase reporter constructs showed that a functional PXR-responsive element located –1839/–1824 base pairs upstream from the translation start site was the primary binding site mediating the rifampicin induction of CYP2C9. This site was previously described as a constitutive androstane receptor-responsive element (CAR-RE). Mutational analysis of 3- and 12-kilobase CYP2C9 promoter fragments indicated that this proximal binding site was essential for rifampicin inducibility, although a cooperative effect could be attributed to a second CAR-RE located at –2899/–2883. In summary, we have demonstrated rifampicin induction of CYP2C9 promoter constructs that is consistent with the magnitude of induction of CYP2C9 protein and mRNA reported in vivo and in primary human hepatocytes, and we have identified the cis-element essential for this response. This is the first report to demonstrate that the nuclear receptor PXR mediates induction of CYP2C9 with rifampicin, phenobarbital, and hyperforin.
Address correspondence to: Dr. Joyce Goldstein, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709. E-mail: goldste1{at}niehs.nih.gov
This article has been cited by other articles:
|
|
 |
|
  Y. Chen, S. Coulter, A. M. Jetten, and J. A. Goldstein Identification of Human CYP2C8 as a Retinoid-Related Orphan Nuclear Receptor Target Gene J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 192 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Toriyabe, K. Nagata, T. Takada, Y. Aratsu, T. Matsubara, K. Yoshinari, and Y. Yamazoe Unveiling a New Essential Cis Element for the Transactivation of the CYP3A4 Gene by Xenobiotics Mol. Pharmacol., March 1, 2009; 75(3): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Surapureddi, R. Rana, J. K. Reddy, and J. A. Goldstein Nuclear Receptor Coactivator 6 Mediates the Synergistic Activation of Human Cytochrome P-450 2C9 by the Constitutive Androstane Receptor and Hepatic Nuclear Factor-4{alpha} Mol. Pharmacol., September 1, 2008; 74(3): 913 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Kramer, A. E. Rettie, M. J. Rieder, E. T. Cabacungan, and R. N. Hines Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression Mol. Pharmacol., June 1, 2008; 73(6): 1751 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Grossman, J. Olson, T. Batchelor, D. Peereboom, G. Lesser, S. Desideri, X. Ye, T. Hammour, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma Neuro-oncol, April 1, 2008; 10(2): 190 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Kanebratt and T. B. Andersson HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans Drug Metab. Dispos., January 1, 2008; 36(1): 137 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Urquhart, R. G. Tirona, and R. B. Kim Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs J. Clin. Pharmacol., May 1, 2007; 47(5): 566 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Meneses-Lorente, C. Pattison, C. Guyomard, C. Chesne, R. Heavens, A. P. Watt, and B. Sohal Utility of Long-Term Cultured Human Hepatocytes as an in Vitro Model for Cytochrome P450 Induction Drug Metab. Dispos., February 1, 2007; 35(2): 215 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Hagedorn, C.-L. Cooke, J. R. Falck, B. F. Mitchell, and S. T. Davidge Regulation of Vascular Tone During Pregnancy: A Novel Role for the Pregnane X Receptor Hypertension, February 1, 2007; 49(2): 328 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Jackson, S. S. Ferguson, M. Negishi, and J. A. Goldstein Phenytoin Induction of the Cyp2c37 Gene Is Mediated by the Constitutive Androstane Receptor Drug Metab. Dispos., December 1, 2006; 34(12): 2003 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Jiang, E. Y. L. Blair, and A. J. McLachlan Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J. Clin. Pharmacol., November 1, 2006; 46(11): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Meijerman, J. H. Beijnen, and J. H.M. Schellens Herb-Drug Interactions in Oncology: Focus on Mechanisms of Induction Oncologist, July 1, 2006; 11(7): 742 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Zhang, S. S. Dehal, T. Ho, J. Johnson, C. Chandler, A. P. Blanchard, R. J. Clark Jr., C. L. Crespi, D. M. Stresser, and J. Wong HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81 Drug Metab. Dispos., May 1, 2006; 34(5): 734 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mu, J. Zhang, S. Zhang, H.-H. Zhou, D. Toma, S. Ren, L. Huang, M. Yaramus, A. Baum, R. Venkataramanan, et al. Traditional Chinese Medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) Activate Pregnane X Receptor and Increase Warfarin Clearance in Rats J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1369 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. DeLozier, S.-C. Lee, S. J. Coulter, B. C. Goh, and J. A. Goldstein Functional Characterization of Novel Allelic Variants of CYP2C9 Recently Discovered in Southeast Asians J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1085 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, G. Kissling, M. Negishi, and J. A. Goldstein The Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Cross-Talk with Hepatic Nuclear Factor 4{alpha} to Synergistically Activate the Human CYP2C9 Promoter J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1125 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Ferguson, Y. Chen, E. L. LeCluyse, M. Negishi, and J. A. Goldstein Human CYP2C8 Is Transcriptionally Regulated by the Nuclear Receptors Constitutive Androstane Receptor, Pregnane X Receptor, Glucocorticoid Receptor, and Hepatic Nuclear Factor 4{alpha} Mol. Pharmacol., September 1, 2005; 68(3): 747 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Mohutsky, D. M. Petullo, and S. A. Wrighton THE USE OF A SUBSTRATE CASSETTE STRATEGY TO IMPROVE THE CAPACITY AND THROUGHPUT OF CYTOCHROME P450 INDUCTION STUDIES IN HUMAN HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 920 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Greenblatt and L. L. von Moltke Interaction of Warfarin With Drugs, Natural Substances, and Foods J. Clin. Pharmacol., February 1, 2005; 45(2): 127 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-F. Yueh, M. Kawahara, and J. Raucy HIGH VOLUME BIOASSAYS TO ASSESS CYP3A4-MEDIATED DRUG INTERACTIONS: INDUCTION AND INHIBITION IN A SINGLE CELL LINE Drug Metab. Dispos., January 1, 2005; 33(1): 38 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wang, R. I. Sanchez, R. B. Franklin, D. C. Evans, and S.-E. W. Huskey THE INVOLVEMENT OF CYP3A4 AND CYP2C9 IN THE METABOLISM OF 17{alpha}-ETHINYLESTRADIOL Drug Metab. Dispos., November 1, 2004; 32(11): 1209 - 1212. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
